Alembic gets USFDA nod for generic cancer treatment medication
The company has received approval from the US Food and Drug Administration (USFDA) to market its product which is a generic version of Hikma Pharmaceuticals USA Inc product, Alembic Pharmaceuticals said in a statement.
ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
With reference to the captioned subject, please find enclosed herewith the intimation dated 10th November, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding lost/misplaced share certificate(s) of the Company for which the shareholder has requested duplicate share certificate(s). We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Board Meeting Intimation for Board Meeting To Consider Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2022
ALEMBIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 ,inter alia, to consider and approve With reference to the captioned matter, the Exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Monday, 14th November, 2022, inter alia to consider and approve Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2022. Pursuant to the Company''s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company which was closed from 1st October, 2022, will reopen 48 hours after the declaration of the financial results. We request you to kindly take note of the above.
Alembic gets USFDA nod for generic pain-relief medication
The company has received final approval from the US Food Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Ketorolac Tromethamine Injection In multiple strengths, the drug maker said in a statement. ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
With reference to the captioned subject, please find enclosed herewith the intimation dated 11th October, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding approval of the request received for issue of Duplicate Share Certificate(s) and issue of letter of confirmation in lieu of the physical share certificate to the registered shareholder(s) in accordance with the provisions of SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated 25th January, 2022. We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Drigesh MittalDesignation :- Company Secretary and Compliance Officer ALEMBIC LTD. - 506235 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the captioned matter, please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2022, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
With reference to the captioned subject, please find enclosed herewith the intimation dated 4th October, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding lost/misplaced share certificate(s) of the Company for which the shareholder has requested duplicate share certificate(s). We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Clarification On Increase In Volume
With reference to your aforementioned email, we would like to inform that the Company is regular in compliance with the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and all required information / announcement etc. is filed with the stock exchanges before it is shared to any other investor / person. We wish to inform you that, to the best of our knowledge, there are no other events, information or announcement (including impending announcement) which may have a bearing on the price / volume behaviour in the scrip. ALEMBIC LTD. - 506235 - Clarification sought from Alembic Ltd
The Exchange has sought clarification from Alembic Ltd on October 3, 2022, with reference to Movement in Volume.The reply is awaited.